ATV and RAL pharmacokinetic parameters in different dosing strategies.

<p>ATV and RAL pharmacokinetic parameters in different dosing strategies.</p

Patients’ characteristics at baseline.

<p>Patients’ characteristics at baseline.</p

Changes from baseline in main laboratory parameters.

<p>ATV/r or ATV: Boosted or Unboosted Atazanavir; RAL: Raletgravir; ALT: Alanine aminotransferase; HDL: High-density lipoprotein; LDL: Low-density lipoprotein.</p

Cumulative probability of treatment success according with ritonavir association.

<p>Survival curves by time to loss of virological response analysis, according to virological failure (A) and treatment failure (B). ATV/r or ATV: Boosted or Unboosted Atazanavir, RAL: Raltegravir.</p

Significant predictors associated with virological failure and therapeutic failure.

<p>Significant predictors associated with virological failure and therapeutic failure.</p

Reasons for stopping dual therapy before week 96 (n = 132).

<p>Reasons for stopping dual therapy before week 96 (n = 132).</p

Study’s flowchart.

<p>* Cohort of HIV-infected patients consulting in infectious department during 1 year. ** Dedicated questionnaire + Hand-Held spirometer.</p

Baseline characteristics of study cohort: comparison included/excluded.

<p>Baseline characteristics of study cohort: comparison included/excluded.</p

Comparison COPD-patients and non-COPD patients.

<p>Comparison COPD-patients and non-COPD patients.</p

Standardized difference between statin users and non users.

<p>Abbreviations: BMI = body mass index, HCV = hepatitis C virus, HBs = hepatitis B, AIDS = acquired immune deficiency syndrome.</p